Kyeongmi Kim

Prof. Dr. Kyeongmi Kim


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ASAN SeungChan
AN SeungChan
HJHak Hoon Jun
Hak Hoon Jun
KKKyeongmi Kim
Kyeongmi Kim
IKIssac Kim
Issac Kim
SCSujin Choi
Sujin Choi
HAHyun-Ju An
Hyun-Ju An
Background/Objectives: Anaplastic thyroid cancer (ATC) is an aggressive and rare cancer with a poor prognosis, and traditional therapies have limited efficacy. This study investigates drug repositioning, focusing on auranofin, a gold-based drug originally used for rheumatoid arthritis, as a potential treatment for ATC. Methods: Auranofin was identified from an FDA-approved drug library and tested on two thyroid cancer cell lines, 8505C and FRO. Antitumor efficacy was evaluated through gene and protein expression analysis using Western blot, FACS, and mRNA sequencing. In vivo experiments were conducted using subcutaneous injections in nude mice to confirm the anticancer effects of auranofin. Results: Auranofin induced reactive oxygen species (ROS) production and apoptosis, leading to a dose-dependent reduction in cell viability, G1/S phase cell cycle arrest, and altered expression of regulatory proteins. It also inhibited cancer stem cell activity and suppressed epithelial–mesenchymal transition. mRNA sequencing revealed significant changes in the extracellular matrix–receptor interaction pathway, supported by Western blot results. In vivo xenograft models demonstrated strong antitumor activity. Conclusions: Auranofin shows promise as a repurposed therapeutic agent for ATC, effectively inhibiting cell proliferation, reducing metastasis, and promoting apoptosis. These findings suggest that auranofin could play a key role in future ATC treatment strategies.

30 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SCSujin Choi
Sujin Choi
KKKyeongmi Kim
Kyeongmi Kim
HYHyunjeong Yeo
Hyunjeong Yeo
GLGyurim Lee
Gyurim Lee
IKIsaac Kim
Isaac Kim
Soonchul LeeSoonchul Lee
Soonchul Lee
MicroRNAs (miRNAs) play a crucial role as oncogenic or tumor suppressors in the pathogenesis and progression of tumors. However, few studies have investigated the exact role of miR-4284 in renal cell carcinoma (RCC). We aimed to investigate the role of miR-4284 as a tumor suppressor in renal cancer cell lines. A498 and Caki-1 were transfected with miR-4284. The Cell Counting Kit-8, colony formation, apoptosis assays, and quantitative reverse transcription–polymerase chain reaction were used to evaluate tumor growth-inhibiting functions. The wound-healing, transwell, and sphere-formation assays were conducted to investigate tumorigenic characteristics. The potential target genes of miR-4284 were predicted and experimentally verified. A xenograft experiment was performed to estimate the tumor-growth-suppressive function of miR-4284. miR-4284 overexpression suppressed proliferation, induced apoptosis, and suppressed tumorigenic features of renal cancer cells. Glutamate decarboxylase 1 (GAD1) was directly targeted by miR-4284. A xenograft mouse model injected with Caki-1 cells transfected with miR-4284 showed significantly decreased tumor growth rate and volume. miR-4284 affected tumor growth, metastasis, and apoptosis of renal cancer cells in vitro and in vivo. These findings highlight the potential of miR-4284 as a target for anticancer miRNA therapeutics in RCC.

14 September 2025 in Medicina
Verified
Journal Article
Open access
PDF file
HSHeejin So
Heejin So
KKKyungsuk Kwon
Kyungsuk Kwon
SJSukhyun Jung
Sukhyun Jung
KKKyeongmi Kim
Kyeongmi Kim
Background and Objectives: Pregnancy induces numerous physiological changes, including hematologic adaptations, which affect complete blood count (CBC) parameters. Existing reference intervals for CBC are often based on non-pregnant populations, potentially limiting their clinical utility during pregnancy. This study aimed to evaluate longitudinal changes in CBC parameters throughout pregnancy in Korean women and to establish gestational age-specific reference intervals. Materials and Methods: This retrospective study, conducted between March and May 2025, included CBC tests consecutively performed on the same individuals at five time points: the first trimester (≤12 weeks), second trimester (13–28 weeks), third trimester (29–40 weeks), delivery day, and the second postpartum day. Additionally, to prevent duplication with the primary cohort, CBC data from pregnant outpatients and non-pregnant controls were also analyzed to establish reference intervals. CBC parameters were measured using an automated hematology analyzer. Reference intervals were established using the 2.5th and 97.5th percentile of the distribution. Results: During pregnancy, white blood cell (WBC) counts increased most significantly during the second trimester, while hemoglobin (Hgb) levels declined most markedly at this stage. Platelet (PLT) counts showed a consistent and progressive decline. The reference intervals for CBC parameters—WBC (×109/L), Hgb (g/dL), and PLT (×109/L)—were 5.11–12.14, 11.3–14.3, and 184–374 in the first trimester; 6.11–13.45, 10.1–13.3, and 164–356 in the second trimester; and 5.62–12.42, 10.1–14.1, and 145–349 in the third trimester, respectively. Conclusions: This study examined longitudinal changes in CBC parameters in Korean pregnant women and provided gestational age-specific reference intervals for CBC. This is expected to help clinicians interpret CBC results in pregnant women.

3 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
SKSegi Kim
Segi Kim
SJSimho Jeong
Simho Jeong
KKKyeongmi Kim
Kyeongmi Kim
JSJunhee Sung
Junhee Sung
DKDo Kyung Kim
Do Kyung Kim
Soonchul LeeSoonchul Lee
Soonchul Lee
Objectives: This study aimed to investigate the relationship between the sarcopenia index (SI), which is derived from serum creatinine and cystatin C levels, and osteoporosis in chronic kidney disease (CKD). Methods: This study initially included patients who underwent dual-energy X-ray absorptiometry (DXA) and serum creatinine and cystatin C testing between 2005 and 2022. Subsequently, patients diagnosed with CKD were selected for the final analysis, totaling 102 patients. Both traditional and new SI were calculated, with each participant categorized into one of two groups (non-osteoporosis and osteoporosis) according to bone mineral density. To enhance statistical validity, the patients were further divided into low- and high-index groups based on the median value of both indices for comparative analysis. The association between SI and the risk of osteoporosis was estimated using multivariable logistic regression analysis. Results: Participants with lower SI values had lower bone mineral density and a higher diabetes mellitus prevalence. The non-osteoporotic group exhibited significantly higher mean values for both traditional and new SI. Multivariable logistic regression analysis identified three statistically significant variables: both indices, sex, and diabetes mellitus. Both traditional and new SI yielded individual odds ratios of 0.906 with estimated areas under the curve of 0.847 for traditional SI and 0.833 for new SI. Conclusions: This study confirmed that both traditional and new SI are associated with osteoporosis in patients with CKD. Therefore, clinicians can raise the suspicion of osteoporosis based on traditional and new SI in patients with CKD, even when DXA results are unavailable.

23 November 2022 in Medicina
Verified
Journal Article
Open access
PDF file
KKKyeongmi Kim
Kyeongmi Kim
SYSIYEONG YOON
SIYEONG YOON
JCJunwon Choi
Junwon Choi
Soonchul LeeSoonchul Lee
Soonchul Lee
Background and Objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to control pain and fever. However, their effect on COVID-19 infected patients has not been fully studied. In this study, we investigated the effect of the duration of NSAIDs use on COVID-19 infection and clinical outcomes. Materials and Methods: In South Korea, 25,739 eligible patients who received COVID-19 testing between 1 January and 31 July 2020, were included in this retrospective observational cohort analysis. Based on the date of the first COVID-19 test for each patient, NSAID prescription dates were used to separate patients into two groups (short-term group: <2 weeks; long-term group: 8–12 weeks). COVID-19 infectivity and clinical outcomes were analyzed. We used the propensity score-matching (PSM) method. Results: Of the 580 patients who had taken NSAIDs before the date of COVID-19 test, 534 and 46 patients were grouped in the short- and long-term NSAID-use groups, respectively. We did not find a statistically significant increased risk of COVID-19 infection (adjustment for age and sex, p = 0.413; adjustment for age, sex, region of residence, comorbidity, Charlson Comorbidity Index, and current use of medication, p = 0.259) or change in clinical outcomes, including conventional oxygen therapy, admission of intensive care unit, artificial ventilation, or death, between the two groups in which the PSM method was applied. Conclusions: The duration of NSAIDs use did not have a statistically significant effect on COVID-19 infectivity or clinical outcomes. However, further studies looking at clinical presentation and laboratory test results in a large number of people should be performed.

5 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KKKyeongmi Kim
Kyeongmi Kim
KKKyung Rae Ko
Kyung Rae Ko
SYSIYEONG YOON
SIYEONG YOON
JCJaiwoo Chung
Jaiwoo Chung
Soonchul LeeSoonchul Lee
Soonchul Lee
Background/Objectives: Legg–Calvé–Perthes disease (LCPD) is characterized by idiopathic avascular necrosis of the femoral head in children. There are several hypotheses regarding the cause of LCPD; however, the exact cause remains unclear. Studies on comorbidities can provide better insight into the disease. We aimed to perform a network analysis to identify the associations between LCPD and comorbidities. Methods: We analyzed patients aged ≤ 12 years with LCPD as defined by ICD-10 codes M91.1, M91.8, and M91.9 registered in the National Health Insurance Service cohort database from 2002 to 2015. A control group was designed using propensity score matching. Comorbidities were identified and network analysis was performed. The identified comorbidities were reclassified into clinical disease groups considering their clinical relevance, and a network map was created using odds ratios. Results: In total, 23 significant disease clusters were identified. Injury-related disease clusters with ICD-10 codes starting with “S” were the most frequent. They were reclassified into 11 disease groups based on clinical relevance. Among these, congenital deformities of hip (Q65) had the highest odds ratio. Congenital deformities of feet (Q66) and other anemia (D64) had a single association with LCPD in the comorbidity network analysis. Conclusions: We confirmed the association between LCPD and comorbidities using a network analysis. The LCPD comorbidity network identified in this study is expected to serve as the basis for future research on LCPD.